Renata Limited, a leading Bangladeshi pharmaceutical company, can now export its Cabergoline 0.5mg tablets to multiple European countries. Cabergoline, a dopamine agonist, treats hyperprolactinemia and Parkinson’s disease.

Renata announced this export approval on September 2 through a filing with the Dhaka Stock Exchange (DSE). The approval from the EU Decentralized Procedure (DCP) opens access to markets in Ireland, France, Portugal, Italy, Denmark, Sweden, the Netherlands, Norway, and Spain.

“This significant milestone reflects Renata’s commitment to expanding its product offerings in the European market with strong competency in developing and delivering low-dosage, high-potency complex products,” Renata said.

Renata will export Cabergoline 0.5mg tablets from its UK MHRA-approved facility. The company ensures that the facility follows strict quality control measures and meets European market demands.

“This product will be distributed across Europe through multiple strategic partnerships, ensuring widespread patient access,” Renata added.

In Bangladesh, the medicine is sold under the name Cabolin. Last year, Renata’s European subsidiary, Renata Pharmaceuticals (Ireland) Limited, also received EU and German approvals for its anti-Parkinson’s therapies, Cabergoletten 1mg and 2mg.

Renata’s latest export achievement reinforces its growing presence in the global pharmaceutical market.

Source: The Business Standard